Valeritas Holdings Revenues Grow on Acceptance of V-Go for Insulin, Analysts Review

Valeritas Holdings, Inc. (NASDAQ: VLRX) is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.


The company’ shares continue to zoom backed by the favorable impact of its recent announcements and the growing popularity of its lead product, i.e. V-Go®. On Oct 2nd, the company presented positive clinical and economic outcomes for V-Go compared to standard multiple daily injections (MDI) insulin therapy for treating people with type 2 diabetes. The results were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany.


Investment highlights – Rapidly Ramping Revenue & Poised for Significant Value Creation.

The management believes that V-Go has the potential to one day become the insulin delivery method of choice for millions of patients with type 2 diabetes and that the revenue potential for Valeritas is substantial.

More recently, On October 10th, the company announced that Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes.


Our members have booked up to 800% with our recent (2018) NASDAQ and NYSE small cap alerts. We will be initiating coverage on another exciting small cap security mid-week this week (10/14/18). View our recent picks, track record and sign up for our real time mobile/text alerts here –


We are very encouraged with both the clinical and economic benefits patients experienced in our study while utilizing V-Go to manage their diabetes,” said Beverly Everitt, APRN, MSN, CDE, BC-ADM, lead author and investigator from Endocrinology Consultants, Virginia Beach, Virginia. “In my opinion, great consideration should be given to the use of V-Go for the management of patients requiring insulin therapy, given the improvements over conventional insulin delivery in glycemic control and economic outcomes.” 


Before this on 7th August, the company announced its financial results and business update for the second quarter ended June 30, 2018.


Second Quarter 2018 Highlights:

  • Revenues in the second quarter grew 36% year-over-year to $6.5 million;
  • Total and new prescriptions for the second quarter in the Company’s targeted accounts grew 22% and 18% year-over-year, respectively.
  • Gross margin increased to 47.6% during the second quarter of 2018, an increase of nearly ten percentage points compared to 37.7% in the second quarter of 2017.
  • Signed exclusive agreements for the distribution of V-Go in Austria and Germany.
  • Presented additional strong data demonstrating the effectiveness and economic benefits of V-Go for people with type 2 diabetes at several major scientific meetings.
  • V-Go was added to the Cigna HealthSpring Part D Plan.


Management’ Guidance: The Company expects 2018 revenue to be between $26 and $28 million. The Company also expects quarterly gross margin to increase on both an annual and sequential basis in 2018, ending the year with a gross margin above 50% for the fourth quarter of 2018. These expectations are based on, among other things, the assumption there will be continued growth in the Company’s targeted accounts and no sequential decline in the Company’s non-targeted accounts.


Robust Pipeline to Drive Long-Term GrowthV-Go® is a platform with the potential to disrupt diabetes & insulin markets

Price Target:

Per, their average twelve-month price target is $3.75, suggesting that the stock has a possible upside of 175.74%. The high price target for VLRX is $4.00, and the low-price target for VLRX is $3.50. Considering all this, the company is in an extremely favorable risk-reward position, and value investors should consider exposure in this sector as the backdrop remains favorable.


Below are the excerpts of recent analyst rating on the script:



Industry Potential:15% share penetration generates ~$1.6B U.S. Opportunity


Quarterly Financial Results (in, thousands):

Revenue –

  • Total revenue for the second quarter of 2018 was $6.5 million, a 36% increase from the second quarter of 2017 and a 7% sequential increase from the first quarter of 2018.
  • The increase in the Company’s revenue was driven by strong prescription growth in the Company’s targeted territories. For the second quarter, total and new prescriptions in targeted accounts grew 22% and 18% year-over-year, respectively.  The Company also experienced 8% year-over-year growth in new prescriptions and 5% sequential growth in total prescriptions in accounts that were not targeted by its sales representatives, which demonstrates the success of the Company’s cost-effective strategy of using a third-party inside sales team and contracted in-service visits.



  • Gross profit in the second quarter of 2018 was $3.1 million, an increase of 71% versus $1.8 million in the same period in 2017. Gross margin increased by nearly ten percentage points to 47.6% versus 37.7% in the second quarter of 2017 due primarily to the increase in unit sales of V-Go, as well as an increase in V-Go’s net selling price and remained constant from the first quarter of 2018.
  • Net loss in the second quarter of 2018 was $11.0 million, a decrease of 9% from $12.0 million in the second quarter of 2017, which was primarily due to improved gross margin.


Liquidity and financial flexibility

  • Total cash and cash equivalents were $33.0 million as of June 30, 2018, compared to $26.0 million on December 31, 2017.
  • The increase in cash was due to the Company’s $26.8 million equity capital raise in April 2018 and an additional $3 million of common stock sold through the Company’s purchase agreement with Aspire Capital, offset by net cash used for operating activities.


Key risk factors and potential stock drivers:

  • The company operation is still at an early stage, and it is yet to demonstrate stable track-record of growing sales and profitability. Therefore, VLRX’ ability to ramp up operations will continue to remain a long-term stock sensitivity factor.
  • Notwithstanding the recent improvement in the operational and marketing profile of the company, VLRX is still a loss-making entity. Therefore, its ability to maintain liquidity and financial flexibility to fund its incremental capital requirements would remain a critical challenge for the company.
  • VLRX operates in a very competitive and dynamic space and only time would differentiate between real winners and laggards. Some of its competitors may have longer operating histories and significantly greater resources than VLRX.
  • As far as choosing an option with a relative advantage is concerned, VLRX is preferred choice with upside potential.


Stock Performance



  • On Monday, Oct 15th, 2018, VLRX was at $1.17 with volume of 718K shares exchanging hands. Market capitalization is $33.806 million. The current RSI is 45.39
  • In the past 52 weeks, shares of VLRX have traded as low as $0.78 and as high as $6.79
  • At $1.17, shares of VLRX are trading below its 50-day moving average (MA) at $1.26 and below its 200-day moving average (MA) at $2.02
  • The present support and resistance levels for the stock are at $1.26 & $1.44 respectively.



Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.